hyperCORE International, a strategic scaling platform that helps clinical research sites and organizations grow through partnership, announced the election of its officers on October 15, 2026. Jeffrey Smyth has been elected President, Seneca Harrison as Vice President, and Claxton Copeland as Secretary, while Dustin Owen will continue serving as Treasurer. The appointments signal a renewed commitment to serving two distinct audiences through one platform: clinical research site networks seeking growth without losing independence, and contract research organizations (CROs) needing efficient access to experienced sites.
The leadership changes come at a pivotal time for the clinical research industry, where site networks face increasing pressure to scale while maintaining autonomy, and CROs demand faster feasibility and broader patient access. hyperCORE's model addresses both challenges by offering site networks shared expertise, business development support, operational collaboration, and strategic partnerships. For CROs, the platform provides a single point of contact to a growing network of high-performing sites, with rapid feasibility turnaround of 48 to 72 hours, broad U.S. geographic reach, and expanded patient access.
Newly elected President Jeffrey Smyth expressed gratitude for the confidence of his fellow partners, stating, "The camaraderie across our network is what makes this group special, and it positions us well for continued growth. I step into this role with excitement as we scale our collective impact for CROs and patients." Nicholas Focil, former President, emphasized the organization's core purpose: "We help our partners scale. That means giving exceptional site networks the support to grow on their own terms, and giving CROs one trusted connection to the sites and patients their studies need. Strong leadership is essential to that mission."
The implications of these appointments extend beyond internal governance. hyperCORE's partner site networks currently include Empathx Clinical Research, FOMAT Medical Research, Optimal Research Sites, QCR Network, and TrueBlue Clinical Research. Its alumni feature Lynd Clinical (formerly ARC), Avacare (formerly Benchmark Clinical Research), Flourish Research (formerly CSP & CTT), Centricity Research (formerly IACT Health, LMC Manna, Aventiv, and Lucas Research), and most recently Alcanza Clinical Research. This track record demonstrates hyperCORE's ability to nurture site networks that eventually scale independently, a testament to its partnership model.
For CROs, the network's scale is substantial: more than 50 sites, 120+ principal investigators, experience across more than 25 therapeutic areas and multiple trial phases, and access to over 3.4 million patients. By consolidating these resources under one strategic connection, hyperCORE reduces the administrative burden on CROs and accelerates study start-up. The new officers bring complementary expertise to guide this evolution, ensuring that hyperCORE remains a vital bridge between sites and sponsors. As the clinical research landscape grows more complex, hyperCORE's refreshed leadership and dual-audience focus position it to drive sustainable growth and improve patient access to trials. For more information, visit hyperCORE International.
